Imatinib dose escalation for chronic phase-chronic ... [Leukemia. 2009] - PubMed

Save items

loading

Related citations in PubMed

Review Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. [Clin Ther. 2012]
Review Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL. Clin Ther. 2012 Feb; 34(2):272-81. Epub 2012 Jan 27.
Review Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. [Cancer. 2010]
Review Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Kantarjian HM, Cortes J, La Rosée P, Hochhaus A. Cancer. 2010 Mar 15; 116(6):1419-30.
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. [Leukemia. 2008]
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, et al. Leukemia. 2008 Jun; 22(6):1200-6. Epub 2008 Apr 10.
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. [Hematol Oncol. 2010]
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Breccia M, Cannella L, Stefanizzi C, Latagliata R, Nanni M, Diverio D, Santopietro M, Federico V, Alimena G. Hematol Oncol. 2010 Jun; 28(2):89-92.
Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. [Cancer. 2005]
Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
Jørgensen HG, Copland M, Holyoake TL. Cancer. 2005 Jan 1; 103(1):210-11.

See reviews... See all...

Cited by 3 PubMed Central articles

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. [Haematologica. 2012]
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. Haematologica. 2012 May; 97(5):731-8. Epub 2012 Feb 7.
Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. [BMC Blood Disord. 2010]
Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor.
Kayastha GK, Gurung P, Acharya PK, Paudyal BP, Hayes B, Zimmerman M, Karki A, Mansfield AS. BMC Blood Disord. 2010 Dec 7; 10:8. Epub 2010 Dec 7.
Review Chronic myelogenous leukemia: treatment and monitoring. [Dtsch Arztebl Int. 2010]
Review Chronic myelogenous leukemia: treatment and monitoring.
von Bubnoff N, Duyster J. Dtsch Arztebl Int. 2010 Feb; 107(7):114-21. Epub 2010 Feb 19.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patient...
Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.
Leukemia. 2009 Jun ;23(6):1193-6. doi: 10.1038/leu.2009.32. Epub 2009 Feb 26 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy.

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information